The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson’s Disease
-
- Akihisa Mori
- Kyowa Kirin Co., Ltd., Tokyo 100-0004, Japan
-
- Jiang-Fan Chen
- Molecular Neuropharmacology Laboratory, Wenzhou Medical University, Wenzhou 325015, China
-
- Shinichi Uchida
- Kyowa Kirin Co., Ltd., Tokyo 100-0004, Japan
-
- Cecile Durlach
- Kyowa Kirin International, Galashiels TD1 1QH, UK
-
- Shelby M. King
- Kyowa Kirin Inc., Bedminster, NJ 07921, USA
-
- Peter Jenner
- Institute of Pharmaceutical Science, Kings College London, London SE1 9NH, UK
説明
<jats:p>The adenosine A2A receptor subtype is recognized as a non-dopaminergic pharmacological target for the treatment of neurodegenerative disorders, notably Parkinson’s disease (PD). The selective A2A receptor antagonist istradefylline is approved in the US and Japan as an adjunctive treatment to levodopa/decarboxylase inhibitors in adults with PD experiencing OFF episodes or a wearing-off phenomenon; however, the full potential of this drug class remains to be explored. In this article, we review the pharmacology of adenosine A2A receptor antagonists from the perspective of the treatment of both motor and non-motor symptoms of PD and their potential for disease modification.</jats:p>
収録刊行物
-
- Molecules
-
Molecules 27 (7), 2366-, 2022-04-06
MDPI AG